Evidence map›Paper›PMID 40952121›Full record

ArticleJournal of virology2025

Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease.

Juan Wang, Xiaohong Sang, Wenyan Zheng, Jasper Fuk-Woo Chan, Jiao Zhou, Yan Xu, Pu Han, Yong Feng, Lifeng Fu, Jessica Oi-Ling Tsang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Juan Wang *School of Life Sciences, Tsinghua University, Beijing, China.ORCID 0009-0009-7530-1274
Xiaohong Sang *Ciechanover Institute of Precision and Regenerative Medicine, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.ORCID 0009-0002-6561-2254
Wenyan Zheng *State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning, China.
Jasper Fuk-Woo Chan *State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.ORCID 0000-0001-6336-6657
Jiao ZhouCiechanover Institute of Precision and Regenerative Medicine, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.
Yan XuThe Chinese University of Hong Kong, Shenzhen Futian Biomedical Innovation R&D Center, Shenzhen, China.ORCID 0009-0009-0216-0394
Pu HanCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Yong FengCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Lifeng FuCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Jessica Oi-Ling TsangState Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Shuofeng YuanState Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Aaron CiechanoverCiechanover Institute of Precision and Regenerative Medicine, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.
Jing AnDivision of Infectious Diseases and Global Public Health, Department of Medicine, School of Medicine, University of California at San Diego, La Jolla, California, USA.ORCID 0000-0003-3865-2269
Kwok-Yung YuenState Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.ORCID 0000-0001-8700-4570
Jianxun QiCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.ORCID 0000-0002-9358-4732
Ziwei HuangSchool of Life Sciences, Tsinghua University, Beijing, China.ORCID 0000-0001-5459-1211

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteases are versatile therapeutic targets for a wide variety of human diseases, including cancer, cardiovascular diseases, and infections by viruses, bacteria, and parasites. The main protease (M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsSARS-CoV-2Viral Nonstructural ProteinsAnimalsCatalytic DomainChlorocebus aethiopsCOVID-19COVID-19 Drug TreatmentCrystallography, X-RayHumansVero CellsVirus ReplicationAntiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsViral Nonstructural Proteinsbiochemical probecatalytic dyadcovalent inhibitormain proteaseSARS-CoV-2

Identifiers

PMID40952121
PMCPMC12548382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.